Safety of English ivy (Hedera helix) leaf extract during pregnancy: retrospective cohort study.

Abdullah Alkattan, Raad Alameer, Eman Alsalameen, Maram Almaary, Mansour Alkhairat, Ahmed Alkhalifah, Fatimah Alghanim, Nashwa Radwan
{"title":"Safety of English ivy (Hedera helix) leaf extract during pregnancy: retrospective cohort study.","authors":"Abdullah Alkattan,&nbsp;Raad Alameer,&nbsp;Eman Alsalameen,&nbsp;Maram Almaary,&nbsp;Mansour Alkhairat,&nbsp;Ahmed Alkhalifah,&nbsp;Fatimah Alghanim,&nbsp;Nashwa Radwan","doi":"10.1007/s40199-021-00415-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>English ivy (Hedera helix) is commonly used to reduce productive cough symptoms by acting as expectorant therapy. The safety of Hedera helix extract during pregnancy was not established yet. This study aims to determine the safety of English ivy leaf extract on newborns.</p><p><strong>Objectives: </strong>To determine the weight, APGAR (Activity-Pulse-Grimace-Appearance-Respiration) score, and health status of the newborns among the studied groups.</p><p><strong>Methods: </strong>A retrospective multicenter cohort study was conducted during the fourth quarter of 2020 on 245 pregnant women and their newborns in two hospitals located in Riyadh, Saudi Arabia. The women were divided into an exposed group (N = 165) who used English ivy leaf extract syrup during pregnancy, and a control group (N = 80) who were not using any natural-pharmaceutical product for cough.</p><p><strong>Results: </strong>The mean weight of the newborns in the exposed group was 3 kg compared to 2.8 kg in the control group (p-value < 0.05). The median APGAR score of the newborns in the exposed group was 8.5/10 compared to 8.0/10 in the control group (p-value > 0.05). There were no significant differences regarding the percentages of full-term and preterm newborns in the exposed and control groups (78.8% vs. 76.3%, and 21.0% vs. 24.0%, respectively, odds ratio [OR] = 0.86, 95% confidence interval [CI] = 0.45-1.63, p-value > 0.05). Regarding the newborns' health complications reported, there was no statistical difference in the percentages of full-term newborns diagnosed with at least one health complication between the exposed and control groups (0.6 vs. 3.8, OR = 0.15, 95% CI = 0.01-1.47, p-value > 0.05).</p><p><strong>Conclusion: </strong>Hedera helix (English ivy) leaf extract syrup was safe to be used in short term during pregnancy for the fetus.</p>","PeriodicalId":10961,"journal":{"name":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","volume":"29 2","pages":"493-499"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602585/pdf/40199_2021_Article_415.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40199-021-00415-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Background: English ivy (Hedera helix) is commonly used to reduce productive cough symptoms by acting as expectorant therapy. The safety of Hedera helix extract during pregnancy was not established yet. This study aims to determine the safety of English ivy leaf extract on newborns.

Objectives: To determine the weight, APGAR (Activity-Pulse-Grimace-Appearance-Respiration) score, and health status of the newborns among the studied groups.

Methods: A retrospective multicenter cohort study was conducted during the fourth quarter of 2020 on 245 pregnant women and their newborns in two hospitals located in Riyadh, Saudi Arabia. The women were divided into an exposed group (N = 165) who used English ivy leaf extract syrup during pregnancy, and a control group (N = 80) who were not using any natural-pharmaceutical product for cough.

Results: The mean weight of the newborns in the exposed group was 3 kg compared to 2.8 kg in the control group (p-value < 0.05). The median APGAR score of the newborns in the exposed group was 8.5/10 compared to 8.0/10 in the control group (p-value > 0.05). There were no significant differences regarding the percentages of full-term and preterm newborns in the exposed and control groups (78.8% vs. 76.3%, and 21.0% vs. 24.0%, respectively, odds ratio [OR] = 0.86, 95% confidence interval [CI] = 0.45-1.63, p-value > 0.05). Regarding the newborns' health complications reported, there was no statistical difference in the percentages of full-term newborns diagnosed with at least one health complication between the exposed and control groups (0.6 vs. 3.8, OR = 0.15, 95% CI = 0.01-1.47, p-value > 0.05).

Conclusion: Hedera helix (English ivy) leaf extract syrup was safe to be used in short term during pregnancy for the fetus.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
妊娠期间英国常春藤叶提取物的安全性:回顾性队列研究。
背景:常青藤(Hedera helix)常被用作祛痰治疗,以减轻生产性咳嗽症状。Hedera helix提取物在怀孕期间的安全性尚未确定。本研究旨在确定英国常青藤叶提取物对新生儿的安全性。目的:了解研究组新生儿的体重、APGAR(活动-脉搏-表情-外貌-呼吸)评分及健康状况。方法:2020年第四季度,对沙特阿拉伯利雅得两家医院的245名孕妇及其新生儿进行了一项回顾性多中心队列研究。这些妇女被分为暴露组(N = 165),她们在怀孕期间使用英国常春藤叶提取物糖浆,而对照组(N = 80)不使用任何天然药物治疗咳嗽。结果:接触组新生儿平均体重为3 kg,对照组为2.8 kg (p值0.05)。暴露组和对照组足月新生儿和早产新生儿的百分比差异无统计学意义(分别为78.8%对76.3%,21.0%对24.0%,优势比[OR] = 0.86, 95%可信区间[CI] = 0.45-1.63, p值> 0.05)。对于报告的新生儿健康并发症,暴露组和对照组之间诊断为至少一种健康并发症的足月新生儿百分比无统计学差异(0.6比3.8,OR = 0.15, 95% CI = 0.01-1.47, p值> 0.05)。结论:长春藤叶提取物糖浆短期内用于妊娠期胎儿是安全的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Correction: Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies. A rare case of phenobarbital-induced leukocytoclastic vasculitis. Deciphering the similarities and disparities of molecular mechanisms behind respiratory epithelium response to HCoV-229E and SARS-CoV-2 and drug repurposing, a systems biology approach. Simulation of drug-drug interactions between breast cancer chemotherapeutic agents and antiemetic drugs. The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1